The risk of esophageal adenocarcinoma is greater in patients with Barrett's esophagus. However, whether this risk can be reduced by a surgical antireflux procedure is unclear.
In this study, investigators from the United States compared esophageal adenocarcinoma in subjects with Barrett's esophagus who underwent surgery, with those who had medical management.
The team used MEDLINE to perform a meta-analysis of the English language literature published between 1966 and 2001.
They reviewed 1247 abstracts. Overall, 34 studies met the team's inclusion criteria.
|Cancer incidence was not significantly different between the 2 groups.|
|American Journal of Gastroenterology|
The team calculated that there were 4678 cumulative patient-years of follow-up in the surgical group, and 4906 patient-years in the medical group.
They determined that the cancer incidence rate was not significantly different between the 2 groups.
There was also no significant difference between cancer rates when the team compared the 2 groups during the last 5 years.
Dr Kathleen Corey's team concluded, "The reported risk of adenocarcinoma in subjects with Barrett's esophagus is low and not significantly decreased by a surgical antireflux procedure".
"Antireflux surgery…should not be recommended as an antineoplastic measure".